A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that lack of effective therapeutic drugs. K-001 is an oral antitumor drug made from active ingredients of marine microorganisms. The current study aimed to evaluate safety and antitumor activity of K-001 in patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jiujie, Yang, Haiyan, Liu, Jue, Chen, Donghui, Hu, Jiong, Zhang, Haiyan, Wang, Yu, Han, Ting, Mao, Tiebo, Jiao, Feng, Biskup, Ewelina, Pan, Yaotian, Liu, Min, Wang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183060/
https://www.ncbi.nlm.nih.gov/pubmed/34098895
http://dx.doi.org/10.1186/s12885-021-08375-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183060/
https://www.ncbi.nlm.nih.gov/pubmed/34098895
http://dx.doi.org/10.1186/s12885-021-08375-6

Ejemplares similares